Analyst consensus rating
Skye Bioscience Analyst Rating: Buy
SKYE is rated Buy by 5 analysts with a $7.60 target. As of 2026-08-21.
Direct answer
Skye Bioscience's consensus rating is Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.60.
Forecast evidence checked August 21, 2026.
Get free Skye Bioscience email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.28
- Average price target
- $7.60
- High price target
- $20.00
- Low price target
- $2.00
- Low target gap
- +613.3%
- Target upside
- +2,610.4%
- High target gap
- +7,032.7%
- Target range width
- 6,419.4%
- Consensus rating
- Buy
- Analysts
- 5
- Evidence date
- August 21, 2026
- Valid through
- August 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Skye Bioscience?
Skye Bioscience has a verified Buy consensus. The same dataset has an average price target of $7.60.
How far are Skye Bioscience's low and high targets from the recorded price?
The low target implies +613.3%, while the high target implies +7,032.7%.
How many analysts are included in Skye Bioscience's consensus?
The verified consensus includes 5 analysts.
How is Skye Bioscience's target upside or downside calculated?
The average target of $7.60 is divided by the recorded price of $0.28, then one is subtracted to produce +2,610.4%. This does not guarantee a future return.
When was Skye Bioscience's analyst forecast verified?
The data was verified on 2026-08-21. The dataset is valid through 2026-08-28.